Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 58Completed 15Recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Unresectable Non-small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Melanoma 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × endostar protein × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

NCT06965231 2025-05-11

FUMS-EDJS2024

Fudan University

Phase 2 Recruiting
58 enrolled
Dermatologic

Melanoma

NCT06055816 2023-09-28

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Zhejiang Cancer Hospital

Phase 2 Recruiting
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡